uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Clewe, Oskar
Publications (8 of 8) Show all publications
Clewe, O., Wicha, S. G., de Vogel, C. P., de Steenwinkel, J. E. M. & Simonsson, U. S. (2018). A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations. Journal of Antimicrobial Chemotherapy, 73(2), 437-447
Open this publication in new window or tab >>A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
Show others...
2018 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 73, no 2, p. 437-447Article in journal (Refereed) Published
Abstract [en]

Background: Identification of pharmacodynamic interactions is not reasonable to carry out in a clinical setting for many reasons. The aim of this work was to develop a model-informed preclinical approach for prediction of clinical pharmacodynamic drug interactions in order to inform early anti-TB drug development.

Methods: In vitro time-kill experiments were performed with Mycobacterium tuberculosis using rifampicin, isoniazid or ethambutol alone as well as in different combinations at clinically relevant concentrations. The multistate TB pharmacometric (MTP) model was used to characterize the natural growth and exposure-response relationships of each drug after mono exposure. Pharmacodynamic interactions during combination exposure were characterized by linking the MTP model to the general pharmacodynamic interaction (GPDI) model with successful separation of the potential effect on each drug's potency (EC50) by the combining drug(s).

Results: All combinations showed pharmacodynamic interactions at cfu level, where all combinations, except isoniazid plus ethambutol, showed more effect (synergy) than any of the drugs alone. Using preclinical information, the MTP-GPDI modelling approach was shown to correctly predict clinically observed pharmacodynamic interactions, as deviations from expected additivity.

Conclusions: With the ability to predict clinical pharmacodynamic interactions, using preclinical information, the MTP-GPDI model approach outlined in this study constitutes groundwork for model-informed input to the development of new and enhancement of existing anti-TB combination regimens.

National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-386326 (URN)10.1093/jac/dkx380 (DOI)000424144300023 ()29136155 (PubMedID)
Funder
Swedish Research Council, 521-2011-3442EU, FP7, Seventh Framework Programme
Available from: 2019-06-24 Created: 2019-06-24 Last updated: 2019-06-24Bibliographically approved
Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. M. & Simonsson, U. S. H. (2018). Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin. Clinical Pharmacology and Therapeutics, 104(6), 1208-1218
Open this publication in new window or tab >>Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
Show others...
2018 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 104, no 6, p. 1208-1218Article in journal (Refereed) Published
Abstract [en]

A crucial step for accelerating tuberculosis drug development is bridging the gap between preclinical and clinical trials. In this study, we developed a preclinical model-informed translational approach to predict drug effects across preclinical systems and early clinical trials using the in vitro-based Multistate Tuberculosis Pharmacometric (MTP) model using rifampicin as an example. The MTP model predicted rifampicin biomarker response observed in 1) a hollow-fiber infection model, 2) a murine study to determine pharmacokinetic/pharmacodynamic indices, and 3) several clinical phase IIa early bactericidal activity (EBA) studies. In addition, we predicted rifampicin biomarker response at high doses of up to 50 mg/kg, leading to an increased median EBA(0-2 days) (90% prediction interval) of 0.513 log CFU/mL/day (0.310; 0.701) compared to the standard dose of 10 mg/kg of 0.181 log/CFU/mL/day (0.076; 0.483). These results suggest that the translational approach could assist in the selection of drugs and doses in early-phase clinical tuberculosis trials.

Place, publisher, year, edition, pages
WILEY, 2018
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-371046 (URN)10.1002/cpt.1102 (DOI)000449645100021 ()29700814 (PubMedID)
Funder
Swedish Research Council, 521-2011-3442EU, FP7, Seventh Framework Programme, 115337
Available from: 2018-12-19 Created: 2018-12-19 Last updated: 2018-12-19Bibliographically approved
Wicha, S. G., Chen, C., Clewe, O. & Svensson, U. S. .. (2017). A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions. Nature Communications, 8, Article ID 2129.
Open this publication in new window or tab >>A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
2017 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 8, article id 2129Article in journal (Refereed) Published
Abstract [en]

Assessment of pharmacodynamic (PD) drug interactions is a cornerstone of the development of combination drug therapies. To guide this venture, we derive a general pharmacodynamic interaction (GPDI) model for ≥2 interacting drugs that is compatible with common additivity criteria. We propose a PD interaction to be quantifiable as multidirectional shifts in drug efficacy or potency and explicate the drugs’ role as victim, perpetrator or even both at the same time. We evaluate the GPDI model against conventional approaches in a data set of 200 combination experiments in Saccharomyces cerevisiae: 22% interact additively, a minority of the interactions (11%) are bidirectional antagonistic or synergistic, whereas the majority (67%) are monodirectional, i.e., asymmetric with distinct perpetrators and victims, which is not classifiable by conventional methods. The GPDI model excellently reflects the observed interaction data, and hence represents an attractive approach for quantitative assessment of novel combination therapies along the drug development process.

National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-339790 (URN)10.1038/s41467-017-01929-y (DOI)000417906800001 ()29242552 (PubMedID)
Funder
Swedish Research Council, 521-2011-3442EU, FP7, Seventh Framework Programme, 115337
Available from: 2018-02-09 Created: 2018-02-09 Last updated: 2018-02-09Bibliographically approved
Clewe, O., Aulin, L., Hu, Y., Coates, A. R. & Simonsson, U. S. (2016). A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro. Journal of Antimicrobial Chemotherapy, 71(4), 964-974
Open this publication in new window or tab >>A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
Show others...
2016 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 71, no 4, p. 964-974Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: Mycobacterium tuberculosis can exist in different states in vitro, which can be denoted as fast multiplying, slow multiplying and non-multiplying. Characterizing the natural growth of M. tuberculosis could provide a framework for accurate characterization of drug effects on the different bacterial states.

METHODS: The natural growth data of M. tuberculosis H37Rv used in this study consisted of viability defined as cfu versus time based on data from an in vitro hypoxia system. External validation of the natural growth model was conducted using data representing the rate of incorporation of radiolabelled methionine into proteins by the bacteria. Rifampicin time-kill curves from log-phase (0.25-16 mg/L) and stationary-phase (0.5-64 mg/L) cultures were used to assess the model's ability to describe drug effects by evaluating different linear and non-linear exposure-response relationships.

RESULTS: The final pharmacometric model consisted of a three-compartment differential equation system representing fast-, slow- and non-multiplying bacteria. Model predictions correlated well with the external data (R(2) = 0.98). The rifampicin effects on log-phase and stationary-phase cultures were separately and simultaneously described by including the drug effect on the different bacterial states. The predicted reduction in log10 cfu after 14 days and at 0.5 mg/L was 2.2 and 0.8 in the log-phase and stationary-phase systems, respectively.

CONCLUSIONS: The model provides predictions of the change in bacterial numbers for the different bacterial states with and without drug effect and could thus be used as a framework for studying anti-tubercular drug effects in vitro.

National Category
Pharmaceutical Sciences Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-273316 (URN)10.1093/jac/dkv416 (DOI)000374232500018 ()26702921 (PubMedID)
Funder
Swedish Research Council, 521-2011-3442EU, FP7, Seventh Framework Programme, 115337
Available from: 2016-01-15 Created: 2016-01-15 Last updated: 2018-01-10Bibliographically approved
Clewe, O., Goutelle, S., Conte, J. E. . & Simonsson, U. S. H. (2015). A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells-using rifampicin as an example. European Journal of Clinical Pharmacology, 71(3), 313-319
Open this publication in new window or tab >>A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells-using rifampicin as an example
2015 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 71, no 3, p. 313-319Article in journal (Refereed) Published
Abstract [en]

The purpose of the study was to develop a drug-unspecific approach to pharmacometric modeling for predicting the rate and extent of distribution from plasma to epithelial lining fluid (ELF) and alveolar cells (AC) for data emanating from studies involving bronchoalveolar lavage (BAL) sampling, using rifampicin (RIF) as an example. Data consisting of RIF plasma concentrations sampled at approximately 2 and 4 h postdose and ELF and AC concentrations quantified from one BAL sample, taken at approximately 4 h postdose, in 40 adult subjects without tuberculosis was used as an example for model development. This study emphasized the usage of drug-specific plasma pharmacokinetics (PK) for a correct characterization of plasma to pulmonary distribution. As such, RIF PK was described using absorption transit compartments and a one compartment distribution model coupled with an enzyme turn-over model. The ELF and AC distribution model consisted of characterization of the rate of distribution of drug from plasma to ELF and AC by two distribution rate constant, k (ELF) and k (AC), respectively. The extent of distribution to ELF and AC was described by unbound ELF/plasma concentration ratio (R (ELF/unbound-plasma)) and unbound AC/plasma concentration ratio (R (AC/unbound-plasma)) which typical values were predicted to be 1.28 and 5.5, respectively. The model together with a drug-specific plasma PK description provides a tool for handling data from both single and multiple BAL sampling designs and directly predicts the rate and extent of distribution from plasma to ELF and AC. The model can be further used to investigate design aspects of optimized BAL studies.

Keywords
Pharmacometrics, Pulmonary distribution, Bronchoalveolar lavage, Epithelial lining fluid, Alveolar cells
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-248443 (URN)10.1007/s00228-014-1798-3 (DOI)000349963800006 ()25620089 (PubMedID)
Available from: 2015-04-02 Created: 2015-03-30 Last updated: 2018-01-11Bibliographically approved
Clewe, O., Karlsson, M. O. & Simonsson, U. S. H. (2015). Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution. Journal of Pharmacokinetics and Pharmacodynamics, 42(6), 699-708
Open this publication in new window or tab >>Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
2015 (English)In: Journal of Pharmacokinetics and Pharmacodynamics, ISSN 1567-567X, E-ISSN 1573-8744, Vol. 42, no 6, p. 699-708Article in journal (Refereed) Published
Abstract [en]

Bronchoalveolar lavage (BAL) is a pulmonary sampling technique for characterization of drug concentrations in epithelial lining fluid and alveolar cells. Two hypothetical drugs with different pulmonary distribution rates (fast and slow) were considered. An optimized BAL sampling design was generated assuming no previous information regarding the pulmonary distribution (rate and extent) and with a maximum of two samples per subject. Simulations were performed to evaluate the impact of the number of samples per subject (1 or 2) and the sample size on the relative bias and relative root mean square error of the parameter estimates (rate and extent of pulmonary distribution). The optimized BAL sampling design depends on a characterized plasma concentration time profile, a population plasma pharmacokinetic model, the limit of quantification (LOQ) of the BAL method and involves only two BAL sample time points, one early and one late. The early sample should be taken as early as possible, where concentrations in the BAL fluid a parts per thousand yen LOQ. The second sample should be taken at a time point in the declining part of the plasma curve, where the plasma concentration is equivalent to the plasma concentration in the early sample. Using a previously described general pulmonary distribution model linked to a plasma population pharmacokinetic model, simulated data using the final BAL sampling design enabled characterization of both the rate and extent of pulmonary distribution. The optimized BAL sampling design enables characterization of both the rate and extent of the pulmonary distribution for both fast and slowly equilibrating drugs.

Keywords
Bronchoalveolar lavage, Pulmonary distribution, Sampling design, Pharmacometrics
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-268392 (URN)10.1007/s10928-015-9438-9 (DOI)000363982800007 ()26316105 (PubMedID)
Funder
Swedish Research Council, 521-2011-3442EU, FP7, Seventh Framework Programme, 115337
Available from: 2015-12-09 Created: 2015-12-04 Last updated: 2018-01-10Bibliographically approved
Clewe, O., Karlsson, M. O., Goutelle, S., Conte, J. E. . & Simonsson, U. S. H. (2013). A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells. Paper presented at The American Conference on Pharmacometrics, May 12-15, 2013, Fort Lauderdale, USA. Journal of Pharmacokinetics and Pharmacodynamics, 40(S1), S68-S69
Open this publication in new window or tab >>A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells
Show others...
2013 (English)In: Journal of Pharmacokinetics and Pharmacodynamics, ISSN 1567-567X, E-ISSN 1573-8744, Vol. 40, no S1, p. S68-S69Article in journal, Meeting abstract (Other academic) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-219421 (URN)000330126000070 ()
Conference
The American Conference on Pharmacometrics, May 12-15, 2013, Fort Lauderdale, USA
Available from: 2014-03-09 Created: 2014-02-28 Last updated: 2017-12-05Bibliographically approved
Clewe, O., Wicha, S. G., de Vogel, C., de Steenwinkel, J. E. .. & Simonsson, U. S.A model informed pre-clinical approach for identification of exposure-response and pharmacodynamic interactions in early tuberculosis drug development.
Open this publication in new window or tab >>A model informed pre-clinical approach for identification of exposure-response and pharmacodynamic interactions in early tuberculosis drug development
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Tuberculosis treatment involves the use of multiple drugs and therefore there is a risk of not only pharmacokinetic interactions but also pharmacodynamic interactions. From many perspectives identification of pharmacodynamic interactions is not reasonable to carry out in a clinical setting. Thus, the aim of this work was to develop a model-informed pre-clinical approach for identification of exposure-response and pharmacodynamic interactions of drug combinations in order to inform early anti-tuberculosis drug development. In vitro time-kill experiments were performed with Mycobacterium tuberculosis using rifampicin, isoniazid or ethambutol alone as well as in different combinations at clinically relevant concentrations. The Multistate Tuberculosis Pharmacometric model was used to characterize the natural growth and exposure-response relationships of each drug after mono-exposure. Pharmacodynamic interactions during combination exposure were characterized using the General Pharmacodynamic Interaction model with successful separation of each drug’s effect on the potency (EC50) of the other drugs. The approach outlined in this work constitutes groundwork for model informed input to the development of new and enhancement of existing anti-tuberculosis combination regimens.

Keywords
tuberculosis, pharmacodynamic interactions, multistate tuberculosis pharmacometric model, general pharmacodynamic interaction model, isoniazid, rifampicin, ethambutol
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-303870 (URN)
Available from: 2016-10-03 Created: 2016-09-26 Last updated: 2018-02-20
Organisations

Search in DiVA

Show all publications